Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma

IMPORTANCE: High-deductible health plans (HDHPs) require high upfront cost-sharing, which has been associated with suboptimal anticancer medication uptake and adherence. Whether HDHP enrollment has limited the affordability and use of lenalidomide therapy among commercially insured patients with mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazowski, Shelley A., Wilson, Lauren, Dusetzina, Stacie B., Zafar, S. Yousuf, Zullig, Leah L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175078/
https://www.ncbi.nlm.nih.gov/pubmed/35671056
http://dx.doi.org/10.1001/jamanetworkopen.2022.15720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175078/
https://www.ncbi.nlm.nih.gov/pubmed/35671056
http://dx.doi.org/10.1001/jamanetworkopen.2022.15720

Ejemplares similares